{"title":"霉酚酸酯治疗神经性皮炎的前景","authors":"B. Reddy, Tiffany Jow, B. Hantash","doi":"10.1586/EDM.13.18","DOIUrl":null,"url":null,"abstract":"Mycophenolate mofetil (MMF), an inhibitor of inosine 5′-monophosphate dehydrogenase, serves to suppress the immune response against alloantigens by hindering purine nucleotide synthesis in immune cells. At present, MMF is US FDA approved for the prevention of allogeneic renal transplant rejection. In this report, the authors demonstrate, to their knowledge, the first case of successful treatment of neurodermatitis complicated by lichen simplex chronicus and prurigo nodularis with MMF.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic prospects of mycophenolate mofetil for the treatment of neurodermatitis\",\"authors\":\"B. Reddy, Tiffany Jow, B. Hantash\",\"doi\":\"10.1586/EDM.13.18\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mycophenolate mofetil (MMF), an inhibitor of inosine 5′-monophosphate dehydrogenase, serves to suppress the immune response against alloantigens by hindering purine nucleotide synthesis in immune cells. At present, MMF is US FDA approved for the prevention of allogeneic renal transplant rejection. In this report, the authors demonstrate, to their knowledge, the first case of successful treatment of neurodermatitis complicated by lichen simplex chronicus and prurigo nodularis with MMF.\",\"PeriodicalId\":12255,\"journal\":{\"name\":\"Expert Review of Dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1586/EDM.13.18\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1586/EDM.13.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Therapeutic prospects of mycophenolate mofetil for the treatment of neurodermatitis
Mycophenolate mofetil (MMF), an inhibitor of inosine 5′-monophosphate dehydrogenase, serves to suppress the immune response against alloantigens by hindering purine nucleotide synthesis in immune cells. At present, MMF is US FDA approved for the prevention of allogeneic renal transplant rejection. In this report, the authors demonstrate, to their knowledge, the first case of successful treatment of neurodermatitis complicated by lichen simplex chronicus and prurigo nodularis with MMF.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
